雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Treatment of Patients with Gastric Mucosa-associated Lymphoid Tissue Lymphoma Refractory to Helicobacter pylori Eradication―Chemotherapy and Rituximab Norihiko Watanabe 1 , Masahiro Iwano 1 , Akiyoshi Nishio 1 , Tadakazu Kondo 2 , Tsutomu Chiba 1 1Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan 2Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan Keyword: 化学療法 , CHOP療法 , 抗体療法 , rituximab , R-CHOP療法 pp.1241-1249
Published Date 2007/7/25
DOI https://doi.org/10.11477/mf.1403101156
  • Abstract
  • Look Inside
  • Reference
  • Cited by

 Because low-grade gastric MALT lymphoma frequently develops in Helicobacter pylori (H. pylori)-infected gastric mucosa and the survival of lymphoma cells depends on H. pylori-specific T cells, the first step in treatment is the eradication of H. pylori in localized gastric MALT lymphoma. Although irradiation therapy can cure most of the patients with H. pylori eradication-resistant lymphoma, the optimum chemotherapy treatment for these patients has not yet been established. Anti-CD20 antibody, rituximab and rituximab plus cyclophosphamide, doxorubicin, vincristine and predonisone (R-CHOP) can induce remission of localized lymphomas refractory to eradication, as well as locally advanced and disseminated lymphomas. Therefore, rituximab and/or R-CHOP could be one of the best options for the patients with H. pylori eradication-resistant lymphoma.


Copyright © 2007, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院

関連文献

もっと見る

文献を共有